Highlights from AUA2025: Advances in NMIBC (2025)
Availability
On-Demand
Expires on May 30, 2026
Cost
$0.00
Credit Offered
1 AMA PRA Category 1 Credit Credit
1 Participation Credit

Highlights from AUA2025: Advances in NMIBC will discuss the best in the latest advancements in Non-Muscle Invasive Bladder Cancer (NMIBC) from the AUA Annual Meeting!

This activity is designed to increase the urologist’s understanding of how to translate the latest clinical guidelines and scientific advances into their routine clinical practice, improving the care of patients with NMIBC. In this interactive discussion, a multidisciplinary panel of experts highlight the latest in treatment of non-muscle invasive bladder cancer (NMIBC) presented throughout the AUA2025, such as plenary sessions and courses.

This educational activity is supported by independent educational grants from:

  • Merck & Co., Inc.
  • ImmunityBio, Inc.
  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology

At the conclusion of this CME activity, participants will be able to:

  1. Recognize recent developments in the management of NMIBC.
  2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events.
  3. Employ current management approaches for NMIBC.
  4. Utilize risk stratification to guide treatment decisions for NMIBC patients.
  5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.
Faculty Disclosures
Name Company Name Relationship Type End Date
Bree, Kelly Nothing relevant to disclose
Arruda, John B. Nothing relevant to disclose
Packiam, Vignesh Veracyte Consultant or Advisor Current
Packiam, Vignesh Urogen Consultant or Advisor 04/01/2025
Packiam, Vignesh Ferring Consultant or Advisor 04/01/2025
Packiam, Vignesh Photocure Consultant or Advisor Current
Porten, Sima Prabodh Photocure Scientific Study or Trial Current
Porten, Sima Prabodh Stryker Consultant or Advisor Current
Porten, Sima Prabodh AstraZeneca Consultant or Advisor Current
Porten, Sima Prabodh Pacific Edge Consultant or Advisor Current
Porten, Sima Prabodh Vesica Health Consultant or Advisor Current
Grivas, Petros Abbvie Consultant or Advisor 01/24/2024
Grivas, Petros Acrivon Therapeutics Scientific Study or Trial Current
Grivas, Petros ALX Oncology Scientific Study or Trial Current
Grivas, Petros Astellas Pharma Consultant or Advisor Current
Grivas, Petros AstraZeneca Consultant or Advisor 01/25/2024
Grivas, Petros Bicycle Therapeutics Consultant or Advisor 05/31/2024
Grivas, Petros Bristol-Myers Squibb Consultant or Advisor 01/26/2024
Grivas, Petros Daiichi Sankyo, Inc. Consultant or Advisor 09/04/2024
Grivas, Petros EMD Serono Consultant or Advisor Current
Grivas, Petros Foundation Medicine Consultant or Advisor 02/12/2025
Grivas, Petros Fresenius Kabi Consultant or Advisor 06/01/2023
Grivas, Petros Genentech Scientific Study or Trial Current
Grivas, Petros Gilead Consultant or Advisor 01/24/2024
Grivas, Petros Merck & Co Consultant or Advisor 02/28/2024
Grivas, Petros Pfizer Consultant or Advisor Current
Grivas, Petros Replimune Consultant or Advisor 07/19/2024
Grivas, Petros Roche Consultant or Advisor 01/27/2024
Grivas, Petros SeaGen Consultant or Advisor 10/23/2023
Grivas, Petros Strata Oncology Consultant or Advisor Current


EDUCATION COUNCIL DISCLOSURE

PDF icon Education Council Disclosures_June 2024.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF icon COI Review Workgroup Disclosures_June 2024.pdf

 

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2025
Expiration Date: May, 2026

Estimated time to complete this activity: 1.00 hours

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.